This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment improved patients’ survival in these patients.

The authors aimed to review immunotherapies available for prostate cancer treatment.

The authors concluded that further research into immunotherapy for prostate cancer is needed to more accurately assess the effect of immunotherapies as a viable treatment option for prostate cancer.

Benign prostatic hyperplasia (BPH) is a condition in men in which the prostate gland is enlarged but not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction.

The prostate goes through two main growth periods as a man ages. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth begins around age 25 and continues during most of a man’s life. Benign prostatic hyperplasia often occurs during the second growth phase.

This study aimed to evaluate post-traumatic stress disorder (PTSD) in patients who have had treatment for cancer. This study found that a number of patients undergoing cancer treatment developed PTSD after treatment and recommended that supports are put in place.